Outcomes | FBG/HbA1c | n | Events, n (%) | Crude OR (95% CI) | p Value | Adjusted OR (95% CI)a | p Value |
---|---|---|---|---|---|---|---|
Secondary Outcomes: after discharge | |||||||
 Poor functional outcomes (mRS of 3–6) at 3 months | Q1 (≤ 0.81) | 214 | 32 (16.4) | Ref |  | Ref |  |
Q2 (0.82–0.91) | 212 | 46 (21.7) | 1.42 (0.87–2.31) | 0.161 | 1.50 (0.85–2.65) | 0.159 | |
Q3 (0.92–1.06) | 210 | 50 (23.8) | 1.64 (1.02–2.65) | 0.043 | 1.16 (0.66–2.05) | 0.601 | |
Q4 (≥ 1.07) | 210 | 72 (34.3) | 2.67 (1.68–4.23) |  < 0.001 | 1.33 (0.75–2.36) | 0.341 | |
 Poor functional outcomes (mRS of 3–6) at 12 months | Q1 (≤ 0.81) | 183 | 52 (28.4) | Ref |  | Ref |  |
Q2 (0.82–0.91) | 189 | 49 (25.9) | 0.88 (0.56–1.39) | 0.589 | 1.16 (0.68–1.99) | 0.582 | |
Q3 (0.92–1.06) | 190 | 57 (30.0) | 1.08 (0.69–1.69) | 0.737 | 0.94 (0.55–1.59) | 0.803 | |
Q4 (≥ 1.07) | 181 | 83 (45.9) | 2.13 (1.38–3.29) | 0.001 | 1.68 (0.97–2.90) | 0.062 |